Our findings on HTN differed; when preinfusion EV NGAL and TIMP-2×IGFBP-7 were added to the clinical model, 3-month HTN prediction increased significantly (by approximately 10%), suggesting there may be a role for biomarkers to identify patients at highest risk of later HTN, requiring close follow-up and nephroprotection. This evidence concerns the gene TIMP1 and hypertensive disorder.